Navega Therapeutics has developed a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific, and long-lasting. Navega Therapeutics has imitated this process by utilizing a novel gene therapy to target pain in a non-permanent way.

Biotechnology

Navega Therapeutics

Ana Moreno

Fernando Aleman

The executive team at Navega Therapeutics has a wealth of experience in research and engineering. The team includes a researcher from the National Institutes of Health, a project engineer from Aztera, and a research associate from The Scripps Research Institute. The team also has a PhD student from CSIC and a visiting research fellow from Purdue University.

CEO and Executive Team

About

Team members

Other teams at Navega Therapeutics

Board of Directors

Founding Team

Leadership Team